--- title: "Klotho: The 'Longevity Hormone' Being Tested to Slow Brain Aging — What the Science Actually Shows (June 16, 2026) | PepTracker Pro Blog" description: "Klotho is a longevity hormone your body makes naturally. A single low-dose injection improved memory in aged monkeys, and a Phase 1 trial is now testing it in older adults. Here's what the evidence shows — and why klotho is a large protein, not a peptide you can buy." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "Klotho: The 'Longevity Hormone' Being Tested to Slow Brain Aging — What the Science Actually Shows (June 16, 2026)", "description": "Klotho is a longevity hormone your body makes naturally. A single low-dose injection improved memory in aged monkeys, and a Phase 1 trial is now testing it in older adults. Here's what the evidence shows — and why klotho is a large protein, not a peptide you can buy.", "datePublished": "2026-06-16", "dateModified": "2026-06-16", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/blog/klotho-longevity-protein-brain-aging-cognition-phase-1-trial-june-16-2026" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://peptrackerpro.com/blog" }, { "@type": "ListItem", "position": 3, "name": "Klotho: The 'Longevity Hormone' Being Tested to Slow Brain Aging — What the Science Actually Shows (June 16, 2026)", "item": "https://peptrackerpro.com/blog/klotho-longevity-protein-brain-aging-cognition-phase-1-trial-june-16-2026" } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Blog](/blog)/ Klotho: The 'Longevity Hormone' Being Tested to Slow Brain Aging — What the Science Actually Shows (June 16, 2026) Research & Compounds Research & Compounds # Klotho: The 'Longevity Hormone' Being Tested to Slow Brain Aging — What the Science Actually Shows (June 16, 2026) PepTracker Pro Research Team June 16, 2026 9 min read ## Table of Contents - [What klotho is, and why longevity researchers are excited](#section-0) - [The monkey study that changed the conversation](#section-1) - [What the broader evidence shows](#section-2) - [Where it stands as a potential treatment](#section-3) - [Klotho is a protein, not a peptide — and 'in a trial' does not mean 'available'](#section-4) - [What to watch next](#section-5) ## What klotho is, and why longevity researchers are excited Klotho is a protein your body makes naturally, named after the Greek Fate who spins the thread of life. The version that matters most for brain aging is alpha-klotho (α-klotho), a hormone cleaved from a membrane-bound protein — mainly in the kidney and brain — and released into the blood and the fluid around the brain. There it acts as a signaling molecule, touching the FGF, insulin/IGF-1, Wnt, and NMDA-receptor pathways that are central to aging and cognition. Interest in klotho began with human genetics: people who carry a variant called KL-VS tend to have higher klotho levels and, on average, score better on tests of memory and thinking. That link between a natural longevity hormone and real-world cognition is what moved klotho from a niche kidney-biology topic to one of the most-watched targets in the science of healthy brain aging. ## The monkey study that changed the conversation The headline result came in 2023, published in Nature Aging by a UCSF-led team. Aged rhesus monkeys given a single injection of klotho showed improved memory — but with an important twist: only the LOW dose worked, while a higher dose did not. The effect lasted up to about two weeks from one injection. Most striking of all, klotho does not appear to cross the blood-brain barrier, so it is not entering the brain and acting directly. That implies klotho kicks off an indirect, downstream cascade — the body translating a peripheral signal into a central, cognitive benefit. Because the monkey protein used was about 96% identical to the human version, the findings were considered unusually relevant to people, which is part of why they generated so much attention. ## What the broader evidence shows Beyond primates, the animal record is substantial. In mice — including old animals and models of Alzheimer's and Parkinson's disease — raising klotho genetically or by injection improved synaptic plasticity, spatial memory, and resilience to neurodegenerative stress, often from a single dose lasting weeks. On the human side, a 2025 meta-analysis pooling roughly 6,600 people reported a positive association between circulating klotho levels and cognitive performance. That association is correlational, not proof that klotho causes better cognition, but it lines up with the genetics and the animal data. Mechanistically, the leading explanation is that klotho enhances signaling through GluN2B-containing NMDA receptors, a pathway tied to learning and memory, and that it can blunt some APOE-associated Alzheimer's risk in models. ## Where it stands as a potential treatment On the strength of this work, a UCSF team led by Dr. Dena Dubal has been advancing a first-in-human Phase 1 trial to test whether a single low-dose klotho injection can improve cognition in healthy older adults, with cognitive testing tracked over roughly three months. The aim is to see whether giving klotho can reproduce the advantage seen in people who naturally make more of it. If early results are encouraging, a larger trial could follow, but that is a multi-year path. Several groups are also exploring gene-therapy approaches to raise klotho rather than injecting the protein. None of this is approved care today — it is research. ## Klotho is a protein, not a peptide — and 'in a trial' does not mean 'available' Two clarifications matter, both because klotho is widely misunderstood online. First, klotho is a large protein, not a small synthetic peptide like BPC-157 or a GLP-1 drug. Its size makes it genuinely hard to deliver as a medicine, and the fact that it does not cross the blood-brain barrier is a scientific puzzle, not a solved delivery problem. Second, klotho is investigational only: it is not approved by the FDA or any regulator, not prescribed, and not a compounded product. The 'klotho' supplements, peptides, or research chemicals sometimes marketed to consumers are not the clinical-grade protein used in these studies, and there is no evidence that buying them raises your klotho or improves your memory. Anyone interested in klotho should follow the trials — not the storefronts. ## What to watch next The signals worth following are concrete: results from the Phase 1 cognition trial in older adults, any move toward a larger Phase 2, and longer-term safety data, since klotho also affects the kidneys, mineral metabolism, and the cardiovascular system. Watch, too, for how researchers solve the dosing puzzle — the monkey data warn that more is not better — and whether gene-therapy or modified-protein approaches prove more practical than repeated injections. Klotho is one of the most promising leads in geroscience for cognition, but it sits firmly in the 'early and unproven in humans' column. The honest summary in mid-2026: a remarkable natural hormone with real animal and genetic support, now finally being tested where it counts — in people. Ready to track your peptide research? [Open PepTracker Pro](https://app.peptrackerpro.com) PepTracker Pro Research Team The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges. ## Citations 1. \[1\] Castner et al. — Longevity factor klotho enhances cognition in aged nonhuman primates (Nature Aging, 2023) [Source](https://www.nature.com/articles/s43587-023-00441-x) 2. \[2\] Is Klotho the key to brain resilience in aging? — Institute on Aging, University of Pennsylvania [Source](https://www.med.upenn.edu/aging/klotho.html) 3. \[3\] KLOTHO-VS heterozygosity, α-klotho protein levels and cognitive performance (PMC, 2025) [Source](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12574126/) 4. \[4\] Could a protein called klotho block dementia and aging? — UC San Francisco [Source](https://www.ucsf.edu/news/2018/01/409711/could-protein-called-klotho-block-dementia-and-aging) **Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. [Read full research disclaimer →](/research-disclaimer) ## Related Articles [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/pep19-endocannabinoid-peptide-visceral-fat-sleep-vs-glp1-june-13-2026) Research & Compounds [ ### A Peptide That Targeted Visceral Fat — and Improved Sleep — Without Lean-Mass Loss: What the Pep19 Trial Shows, and How It Differs From GLP-1s — June 13, 2026 ](/blog/pep19-endocannabinoid-peptide-visceral-fat-sleep-vs-glp1-june-13-2026) An early human trial of Pep19 — a synthetic intracellular peptide that works through the endocannabinoid system — cut visceral fat by about 17% and improved sleep over 60 days, with no lean-mass loss and no reported side effects. That combination is unusual. Here's what the data actually show, why the endocannabinoid mechanism is both promising and historically fraught, and how Pep19 differs from the GLP-1 and amylin drugs dominating the obesity conversation. PepTracker Pro Team June 13, 2026 9 min read Pep19endocannabinoid peptideendocannabinoid system [Read](/blog/pep19-endocannabinoid-peptide-visceral-fat-sleep-vs-glp1-june-13-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026) Research & Compounds [ ### The Race to Put Amylin in a Pill: ACCG-2671 Enters the Clinic, and How Oral Amylin Stacks Up Against Injectable Amylin and GLP-1 — June 14, 2026 ](/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026) Amylin has become the obesity field's favorite non-GLP-1 mechanism — but almost every amylin drug is an injection. Structure Therapeutics just started first-in-human testing of ACCG-2671, an oral, once-daily small-molecule amylin agonist. Here's what amylin does, why an oral version matters, how ACCG-2671 compares to amycretin, eloralintide, cagrilintide, and petrelintide, and why 'in a Phase 1 trial' is very different from 'available to buy.' PepTracker Pro Team June 14, 2026 9 min read ACCG-2671oral amylinamylin receptor agonist [Read](/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/oral-glp1-pill-race-conveglipron-hdm1002-vs-orforglipron-danuglipron-june-15-2026) Research & Compounds [ ### The Oral GLP-1 Pill Race Widens: Conveglipron (HDM1002) Joins Orforglipron in the Hunt for a Needle-Free Weight-Loss Drug — June 15, 2026 ](/blog/oral-glp1-pill-race-conveglipron-hdm1002-vs-orforglipron-danuglipron-june-15-2026) Conveglipron (HDM1002) is an oral, once-daily small-molecule GLP-1 receptor agonist from Huadong Medicine now in Phase 2 for obesity and Phase 3 for type 2 diabetes. Here's how the GLP-1 'pill' race is shaping up against orforglipron and danuglipron — and why an oral small molecule is not the same thing as a peptide. PepTracker Pro Team June 15, 2026 9 min read conveglipronHDM1002oral GLP-1 [Read](/blog/oral-glp1-pill-race-conveglipron-hdm1002-vs-orforglipron-danuglipron-june-15-2026) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.